KESHO

Implementing Precision Oncology in LMICs
2026-07-30 19:30 - 20:30 (Africa/Nairobi)
Implementing Precision Oncology in LMICs:
From Diagnosis to Clinical Decision-Making
Date: 30th July 2026
Time: 7 PM – 8:30 PM EAT
Speaker
Prof. Shahin Sayed
Associate Professor & Consultant, Anatomical Pathology and Cytology, Department of Pathology, Medical College, Aga Khan University; Chair & Laboratory Director. Pathology, AKUH, N
The Diagnostic Foundations of Precision Oncology: Pathology, Biomarkers and Molecular Testing
Speaker
Prof. Chite Asirwa
Medical Oncologist & Hematologist; CEO, International Cancer Institute
Precision Oncology in LMICs: Current Landscape, Clinical Application and the Road Ahead
Moderator
Prof. Nicholas Abinya
Consultant Medical Oncologist, Nairobi Hospital Cancer Centre
Summary
This session examined what meaningful precision oncology looks like in low- and middle-income countries, connecting clinical decision-making with pathology, molecular diagnostics, patient factors, health-system capacity and access to treatment.
A central theme was that precision oncology is broader than genomic sequencing. Prof. Chite Asirwa described it as the integration of clinical, pathological, molecular, environmental and patient-specific information across diagnosis, prognosis, treatment selection and monitoring. Used well, this approach can reduce ineffective empirical treatment, limit unnecessary toxicity and direct limited resources towards interventions most likely to benefit the patient.
Prof. Shahin Sayed focused on the diagnostic foundations that make precision care possible. High-quality tissue, correct fixation and handling, validated assays, quality assurance and clinically useful reporting all determine whether a molecular result can be trusted. The discussion reinforced that advanced testing cannot compensate for weak foundational pathology, and that essential immunohistochemistry and biomarker testing remain an important starting point for many settings.
The session also addressed Africa’s underrepresentation in genomic datasets and the challenge of interpreting variants when locally relevant reference data are limited. Molecular results need clinical context and, where possible, multidisciplinary interpretation. Liquid biopsy and circulating tumour DNA were discussed as promising tools for selected applications, but standardisation, quality control and careful use remain important, particularly when considering screening.
Implementation was therefore framed as a phased health-system journey rather than a technology purchase. Strong pathology services, reliable essential biomarkers, regional molecular capacity, better patient navigation, financing and locally generated data must develop together. Across the session, a consistent message emerged: precision oncology has greatest value when a reliable test leads to a clinically meaningful decision and an accessible treatment pathway.
Key Takeaways

Precision oncology integrates clinical, pathological, molecular and patient-specific information rather than genomics alone.
Accurate pathology, specimen quality and laboratory quality assurance are foundational to every precision treatment decision.
Essential biomarkers and immunohistochemistry should be strengthened before indiscriminate expansion into complex testing.
African genomic data and multidisciplinary interpretation are needed to improve the relevance of molecular results.
Testing has limited value when results cannot be linked to accessible treatment, making financing and patient navigation part of precision care.

Continue the learning
This summary captures only part of the discussion. To request the full session recording, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.

Management of Treatment-Induced Neurotoxicity
2026-07-23 19:30 - 20:30
Management of Treatment-Induced Neurotoxicity session
23rd July 2026, 7–8:30 PM EAT,
Featuring Dr. Herman Ekea, Dr. Karishma Sharma, and Dr. Juzar Hooker

Click to Register

Advancing Cardio-Oncology in East Africa
2026-07-16 19:00 - 20:30
Advancing Cardio-Oncology in East Africa
From Evidence to Everyday Practice

Date: Thursday, 16th July 2026
Time: 7:00 PM – 8:30 PM EAT

Speakers

Dr. Anne Mwirigi;

Consultant Haematologist & Assistant Professor | Aga Khan University Hospital, Nairobi

Dr. Kieran Mwazo

Consultant Cardiologist | Head of the Cardiology Division | Coast General Teaching and Referral Hospital, Mombasa

Dr. Joseph Abuodha

Consultant Medical Oncologist | Department of Haematology and Oncology | Aga Khan University Hospital, Nairobi
Moderator

Prof. Arjun Ghosh

Consultant Cardiologist | Barts Heart Centre, St. Bartholomew’s Hospital | London & University College London Hospital
Summary
This joint KESHO and Kenya Cardiac Society session explored how cardiovascular care can be integrated into cancer treatment from baseline assessment through active therapy and long-term survivorship.
A central theme was that advances in cancer treatment have created a growing population of survivors while also expanding the range of potential cardiovascular effects. Dr. Anne Mwirigi set the scene by tracing the evolution of cancer therapy and highlighting how conventional chemotherapy, targeted treatments and newer agents may affect the heart and vascular system in different ways.
Dr. Kieran Mwazo brought the discussion into the East African setting, emphasising that cancer and cardiovascular disease share several risk factors and frequently coexist. Baseline assessment, optimisation of existing cardiovascular disease and structured surveillance can help identify patients who need closer monitoring. ECG, echocardiography, global longitudinal strain, cardiac biomarkers and advanced imaging were discussed as tools for detecting treatment-related injury before it becomes clinically advanced.
Through clinical cases, Dr. Joseph Abuodha illustrated the complexity of decisions when cardiac toxicity develops during potentially life-prolonging cancer treatment. Bradyarrhythmias, changes in cardiac function and suspected treatment-related myocardial injury highlighted the need to consider both oncological benefit and cardiovascular risk rather than automatically prioritising one condition over the other. Shared decision-making and close collaboration between specialties were repeatedly emphasised.
The session also looked beyond individual cases to the systems needed for cardio-oncology in Kenya and the region, including integrated referral pathways, locally adapted protocols, workforce development and stronger data collection. Across the session, a consistent message emerged: cardio-oncology is about protecting cardiovascular health without unnecessarily compromising effective cancer treatment.
Key Takeaways

Cardiovascular assessment should begin before potentially cardiotoxic cancer treatment is started.
Modern cancer therapies can produce a broad range of cardiovascular effects beyond heart failure alone.
Risk-adapted surveillance using ECG, echocardiography, strain and biomarkers can support earlier detection of toxicity.
Treatment decisions should balance oncological benefit with cardiovascular risk through multidisciplinary and shared decision-making.
East Africa needs stronger cardio-oncology pathways, training, locally relevant protocols and regional data.

Continue the learning
This summary captures only part of the discussion. To request the full session recording, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.

Management of Endometrial Cancer
2026-07-09 19:00 - 20:30
A Multidisciplinary Approach in the Management of Endometrial Cancer
📅 9th July 2026
⏰ 7PM – 8:30PM EAT
Join our expert panel:
👨‍⚕️ Dr. Alfred Mokomba — Surgical Management and Risk Stratification
👩‍⚕️ Dr. Catherine Nyongesa — Adjuvant Radiotherapy and Multidisciplinary Decision-Making
🎙️ Moderated by Dr. Edward Sang
Summary
This session examined endometrial cancer through a multidisciplinary lens, linking early recognition and tissue diagnosis with surgical planning, molecular risk classification and adjuvant treatment.
A central theme was that treatment decisions increasingly depend on both traditional clinicopathological risk factors and tumour biology. Dr. Catherine Nyongesa reviewed stage, grade, depth of myometrial invasion, lymphovascular space invasion and histology alongside the molecular groups defined by POLE mutation, mismatch repair deficiency, non-specific molecular profile and p53 abnormality. The discussion highlighted the practical value of mismatch repair and p53 immunohistochemistry, which can help refine prognosis and guide treatment even where broader molecular testing is limited.
Radiotherapy was presented as a risk-adapted component of care. Vaginal brachytherapy remains an important option for appropriately selected high-intermediate-risk patients, while pelvic external beam radiotherapy is reserved for patients with greater pelvic or nodal risk. In higher-risk disease, particularly stage III and p53-abnormal tumours, chemotherapy and combined-modality approaches become increasingly relevant.
Dr. Alfred Mokomba focused on the diagnostic and surgical pathway. Postmenopausal bleeding was emphasised as a warning sign that should prompt investigation rather than reassurance. Endometrial sampling should establish histology before definitive surgery, supported by imaging and appropriate staging. The extent of surgery and nodal assessment should then reflect disease stage, histology and risk rather than following a uniform approach.
Across the session, a consistent message emerged: endometrial cancer outcomes depend on getting the sequence right from the beginning. Early recognition, accurate pathology, risk-adapted surgery and coordinated adjuvant treatment allow the multidisciplinary team to individualise care while using available resources more effectively.
Key Takeaways

Postmenopausal bleeding should prompt timely investigation and tissue diagnosis.
Stage, histology, myometrial invasion, lymphovascular invasion and molecular class all contribute to risk stratification.
Mismatch repair and p53 immunohistochemistry can provide clinically useful molecular information in resource-constrained settings.
Brachytherapy, pelvic radiotherapy and chemotherapy should be selected according to recurrence risk and tumour biology.
Surgery should be planned within a multidisciplinary pathway and followed by review of final pathology and adjuvant needs.

Continue the learning
This summary captures only part of the discussion. To request the full session recording, contact the KESHO Secretariat. KESHO members can access CME recordings and revisit expert-led sessions across haematology and oncology throughout the year. Join KESHO to access the full CME learning library.

Sickle Cell Disease
2026-06-25 19:30 - 20:30
SICKLE CELL DISEASE: FROM NEWBORN DETECTION TO LONG-TERM OUTCOMES

Moderator: Dr. Fatmah Abdallah
Speakers: Dr. Bernard Awuonda and Dr. Sophie Uyoga

This session examined sickle cell disease through the full patient pathway, from newborn detection and early diagnosis to long-term care, survival and health-system readiness.
Dr. Bernard Awuonda opened the session by situating sickle cell disease as an inherited haemoglobin disorder and emphasising the importance of public education in reducing stigma. The discussion highlighted that sickle cell disease is not contagious and that clear communication with families and communities is essential for improving understanding, genetic counselling and health-seeking behaviour.
A major focus of the session was the burden of sickle cell disease in sub-Saharan Africa and Kenya. Dr. Awuonda noted that without timely intervention, many children born with sickle cell disease in high-burden settings die before the age of five. This framed the case for newborn screening as a life-saving public health intervention, rather than a specialist service alone.
The discussion explored screening modalities, including point-of-care testing and laboratory-based approaches, and highlighted the importance of linking screening to action. Early detection only improves outcomes when it is followed by caregiver education, prophylactic care, vaccination, access to hydroxyurea where appropriate, routine monitoring and clear referral pathways.
Dr. Sophie Uyoga shared experience from Kilifi, where structured sickle cell care has combined clinical service delivery, research, patient follow-up and community engagement. The session highlighted how early testing, routine monitoring, access to hydroxyurea and caregiver education can improve survival and health-seeking behaviour.
The discussion also addressed the realities of long-term care, including transition from paediatric to adult services, psychosocial support, affordability, access to diagnostics, transfusion planning and the importance of maintaining patients in care. The speakers emphasised that sickle cell disease should not be viewed as a death sentence. With early diagnosis, structured follow-up and supportive systems, patients can live fuller and longer lives.
The session reinforced the need to operationalise infant screening policy, strengthen financing, improve point-of-care capacity, support data systems and build care pathways that connect newborn screening to lifelong care.
Key Takeaways

Newborn screening is critical for early identification and timely intervention in sickle cell disease.
Screening must be linked to care, including caregiver education, prophylaxis, vaccination, routine monitoring and referral pathways.
Sickle cell disease is inherited and not contagious; community education remains important for reducing stigma.
Hydroxyurea, routine monitoring and structured clinical follow-up can reduce complications and improve outcomes.
Transition from paediatric to adult care requires stronger planning, psychosocial support and retention strategies.
Policy, financing, data systems and point-of-care testing are essential for scaling sickle cell care across Kenya.

Nutrition into Oncology
2026-06-18 19:00 - 20:30
Integrating Nutrition into Oncology Practice
Fueling Better Outcomes
📅 Date: 18th June 2026
🕖 Time: 7 PM – 8:30 PM EAT
🏅 CPD Accredited
MODERATOR
Kennedy Okinda
Oncology Nutrition Specialist, Mwai Kibaki Referral Hospital
SPEAKER
Njoki Karanja
Oncology Nutrition Specialist
Nutrition in Cancer Care: From Treatment to Recovery
SPEAKER
Dr. Andrew Odhiambo
Medical Oncologist, The Nairobi Hospital; Thematic Head & Program Director, Medical Oncology, UON
The Clinical Impact of Nutrition on Cancer Outcomes

Strengthening Haemato-Oncology Care
2026-06-11 19:00 - 20:30
STRENGTHENING HAEMATO-ONCOLOGY CARE THROUGH PALLIATIVE CARE AND RESEARCH EXCELLENCE

Moderator: Prof. John Weru
Speaker: Prof. Sayed Karar
Date: 11 June 2026

This session examined palliative care as a critical component of quality and comprehensive haemato-oncology care. The discussion challenged the misconception that palliative care belongs only at the end of life and instead presented it as an added layer of support that can be introduced early, alongside active treatment.
A central theme was the distinction between palliative care and hospice. Prof. Sayed Karar emphasized that palliative care can support patients and families at any stage of serious illness, including during chemotherapy, radiotherapy or other disease directed treatment. Hospice care, by contrast, is generally associated with advanced disease when curative options are no longer appropriate. The discussion framed palliative care as a holistic service that addresses pain, symptoms, psychological distress, spiritual concerns, social needs and family burden.
The session also situated palliative care within the African and Kenyan context. Prof. Karar highlighted the large unmet need for palliative care across the continent, the uneven availability of services, limited access to opioids and the continued underuse of affordable medicines such as morphine. Local studies were used to show how research can change practice, including ICU trigger models that help identify patients who should receive timely palliative care review.
Through case scenarios, the discussion explored difficult conversations, symptom control, prognostication, end of life feeding, dialysis decisions, family conflict and the role of faith and hope in care decisions. Practical tools such as the SPIKES framework were discussed as a way to support clear, compassionate communication. The session also reinforced the importance of identifying the appropriate decision maker, using plain language and allowing families time to process serious news.
Across the session, a consistent message emerged: palliative care is not about withdrawing care. It is about strengthening care, relieving suffering, supporting decision making and helping patients and families navigate serious illness with dignity.
Key Takeaways

Palliative care should be introduced early and can run alongside active haemato-oncology treatment.
Hospice and palliative care are related but not the same; palliative care is appropriate at any stage of serious illness.
Pain control requires careful assessment, stepwise treatment, safe opioid use and attention to side effects such as constipation.
Difficult conversations need preparation, privacy, clear language, empathy and structured follow up.
Local palliative care research can influence practice, including the use of triggers to identify patients who need timely review.
Every clinician should have basic palliative care skills, especially in settings where specialist services are limited.

The Brain Tumour Journey
2026-05-28 19:00 - 20:30
Speakers: Dr. Michael Magoha; Dr. Sarah Muma; Dr. Parmenas Minda Okemwa
Moderator: Mr. David L. Oluoch-Olunya
The Brain Tumour Journey brought together neurosurgery, paediatric haemato-oncology and neuropathology perspectives to examine how multidisciplinary collaboration can improve care for patients with brain tumours. The session positioned brain tumour management as a continuum, from first symptoms and referral to surgery, pathology, oncology treatment, rehabilitation, follow-up and family support.
Dr. Michael Magoha opened the session by reframing the brain tumour journey around the patient experience. He noted that brain tumours often carry fear and uncertainty, yet they are not a single diagnosis or a uniform prognosis. With more than 150 tumour types and subtypes, the patient’s pathway can vary widely. His presentation highlighted the role of patient navigation in helping individuals move through imaging, surgery, pathology, endocrine review, oncology care and long-term follow-up without being lost in fragmented systems.
Dr. Sarah Muma focused on the multidisciplinary management of childhood brain tumours in Kenya. She highlighted that brain and CNS tumours appear under-recognised in local and African childhood cancer data, suggesting delays in diagnosis and referral. Children may present with persistent headaches, vomiting, visual changes, seizures, gait or coordination problems, abnormal head growth, behavioral changes or endocrine-related symptoms. The discussion emphasized the need for a higher index of suspicion, especially when symptoms are progressive, recurrent or not responding as expected.
The session also examined Kenyan system-level challenges, including limited access to timely imaging, prolonged pathways between surgery and radiotherapy, scarcity of formal paediatric neuro-oncology programs and treatment abandonment. Dr. Muma described the value of neuro-oncology multidisciplinary clinics, where patients and families can receive coordinated input from neurosurgery, oncology, radiology, pathology, rehabilitation, counselling and navigation teams within a more structured care pathway.
Dr. Parmenas Minda Okemwa closed the presentations by discussing the principles and diagnostic challenges of brain tumour pathology. He emphasized that pathology remains the gold standard for diagnosis, but modern brain tumour care increasingly depends on integrated reporting that combines clinical context, radiology, histology, immunohistochemistry and molecular testing. His presentation underscored the need for adequate tissue sampling, stronger neuropathology capacity, expanded diagnostic panels, molecular testing access and regular multidisciplinary tumour board discussions.
Across the session, the message was clear: improving brain tumour outcomes requires coordinated systems, not isolated excellence. Timely diagnosis, accurate pathology, surgical expertise, oncology planning, patient navigation, rehabilitation and survivorship support must work together if patients are to receive care that is clinically sound, humane and sustainable.
Key Takeaways

Brain tumour care is a journey, not a single event. Patients often require coordinated input across imaging, surgery, pathology, oncology treatment, rehabilitation and follow-up.
Patient navigation can reduce fragmentation. Navigators help patients and families move through complex health systems and reduce the risk of missed appointments, delayed reviews or incomplete follow-up.
Children may present with subtle or progressive symptoms. Persistent headaches, seizures, visual changes, gait problems, behavioural changes or endocrine symptoms should prompt a high index of suspicion.
Multidisciplinary clinics can shorten delays. Same-day or coordinated review by several specialists can improve treatment planning and reduce the burden on families.
Accurate diagnosis depends on integrated pathology. Histology remains central, but immunohistochemistry and molecular testing increasingly guide classification, prognosis and treatment options.
Kenya’s neuro-oncology systems are advancing but need strengthening. Referral pathways, registries, specialist training, diagnostic capacity, molecular testing access and survivorship systems remain key priorities.

Bladder Cancer Care
2026-05-21 19:00 - 20:30
SPEAKERS: Dr. Patrick Mbuthia, Dr. Helena Musau, Dr Mohammed Ezzi
Date: 21st May 2026
Moderator: Dr. Sitna Mwanzi
This session examined bladder cancer through a multidisciplinary lens, bringing together surgical, radiotherapeutic and systemic treatment perspectives across the continuum of care.
A central theme was the need for accurate staging and risk-adapted management. Dr. Patrick Mbuthia discussed the role of transurethral resection of bladder tumour (TURBT) in diagnosis, staging and treatment, particularly for non-muscle invasive disease. The importance of complete resection, adequate detrusor muscle in the specimen, careful imaging and attention to complications was emphasized as central to subsequent treatment decisions.
Dr. Helena Musau highlighted the evolving role of radiotherapy in bladder preservation, especially through tri-modality therapy combining maximal TURBT, concurrent chemoradiation and structured response assessment. The discussion also addressed patient selection, surveillance, salvage options, palliative radiotherapy for symptoms, and the value of newer radiotherapy techniques in reducing toxicity while preserving quality of life.
Dr. Mohammed Ezzi reviewed systemic treatment across non-muscle invasive, muscle invasive and metastatic bladder cancer. He outlined the role of intravesical therapy, BCG, cisplatin eligibility, immunotherapy, maintenance strategies and emerging options such as antibody-drug conjugates and targeted agents, while noting that cost and availability continue to shape real-world treatment in Kenya.
Across the session, a consistent message emerged: improving bladder cancer outcomes requires timely diagnosis, high-quality TURBT, multidisciplinary decision-making and treatment pathways that reflect both evidence and local access reality.
Key Takeaways

Bladder cancer management depends on accurate staging and distinction between non-muscle invasive and muscle invasive disease.
High-quality TURBT with adequate muscle sampling is central to diagnosis and treatment planning.
Trimodality therapy offers bladder preservation for carefully selected patients.
Systemic therapy is rapidly evolving with immunotherapy, maintenance approaches and antibody-drug conjugates.
Local data are needed to address African patterns of disease, including schistosomiasis-associated squamous cell carcinoma.

Melanoma Care in Practice: Integrating Dermatology, Surgery & Oncology
2026-05-14 19:00 - 20:30
Moderator: Dr Stephen Chege
Date: 14th May 2026
SPEAKERS: Dr. Hannah Wanyika, Dr. Esther Gathura, Dr. Angela McLigeyo
This session examined melanoma care across the clinical pathway, from recognition of suspicious skin lesions to biopsy, excision, reconstruction, staging and systemic treatment.
A central theme was the importance of early suspicion and timely tissue diagnosis. Dr. Hannah Wanyika highlighted practical indications for biopsy, including new or changing pigmented lesions, non-healing ulcers, evolving moles and lesions that differ from surrounding skin. The discussion reinforced the use of the ABCDE approach and the “ugly duckling” sign, while emphasizing that changing lesions on the palms, soles, nails and scalp should not be dismissed.
Dr. Esther Gathura explored the surgical and reconstructive dimensions of melanoma care, particularly the realities of acral melanoma, which is common in African populations and often presents late. She emphasized the role of mapping biopsies, Breslow thickness, ulceration, nodal assessment and multidisciplinary planning in balancing oncologic safety with function, especially for weight-bearing areas of the foot.
Dr. Angela McLigeyo outlined the major advances in systemic therapy for advanced melanoma, including immune checkpoint inhibitors, targeted therapy and emerging treatment strategies. While immunotherapy has transformed outcomes globally, the session also acknowledged access, affordability and the urgent need for local data to guide treatment decisions in Kenya and the region.
Across the session, a consistent message emerged: optimal melanoma care depends on early recognition, accurate biopsy, careful staging, function-preserving surgery and realistic access to effective systemic therapy.
Key Takeaways

Changing pigmented lesions, non-healing ulcers and suspicious nail or acral lesions require timely biopsy.
The ABCDE rule and “ugly duckling” sign remain useful tools in clinical assessment.
Acral melanoma presents distinct diagnostic and surgical challenges in African settings.
Surgical management must balance clear margins, staging and functional reconstruction.
Immunotherapy and targeted treatment have changed advanced melanoma care, but access and local evidence remain key challenges.

From Data to Discovery: Leveraging Registries and Clinical Insights to Advance Research
2026-05-07 19:00 - 20:30
Moderator: Rebecca Mwakichako
Date: 7th May 2026
Speakers: Dr. Thomas Chatzikonstantinou, Ms. Anne Korir
This session examined how routine clinical data can be transformed into meaningful research evidence, with a focus on real-world data, clinical registries and everyday documentation as a foundation for local oncology research.
A central theme was the value of real-world evidence as a complement to randomized controlled trials. Dr. Thomas Chatzikonstantinou outlined how registries and clinical databases can help answer questions on treatment patterns, long-term outcomes, low-prevalence biomarkers, health economics and implementation across diverse settings. He emphasized that good research begins with realistic questions, clear endpoints and attention to data quality.
Ms. Anne Korir grounded the discussion in the Kenyan cancer registry experience, highlighting how paper files, unstructured notes, missing staging information, weak follow-up documentation and inconsistent residence or risk-factor data can limit the research value of clinical records. She underscored the need for standardization, digitization, regular data cleaning and ethical governance.
Across the session, a consistent message emerged: every clinical encounter can contribute to discovery when documentation is structured, complete and designed with future learning in mind.
Key Takeaways

Real-world data complements clinical trials by showing how care is delivered in routine practice.
Routine clinical notes can generate locally relevant oncology research questions.
Standardized documentation is essential for usable research and registry data.
Cancer registries remain critical for surveillance, policy and outcome tracking.
Collaboration between clinicians, registries and research institutions can strengthen local evidence generation.

Multidisciplinary Management of Testicular Cancer
2026-04-30 19:00 - 20:30
Moderator: Dr. Muigai Mararo
Speakers: Dr. Dedan Opondo, Dr. Joseph Abuodha, Dr. George Ogweno
Date: 30 April 2026

This session marked Testicular Cancer Awareness Month with a multidisciplinary discussion on diagnosis, primary management, advanced disease, relapse and fertility preservation.
A central theme was that testicular cancer is highly curable when investigated and managed promptly, but cure depends on disciplined staging and risk stratification. Dr. Dedan Opondo outlined the importance of early clinical recognition, scrotal ultrasound, serum tumour markers, cross-sectional imaging and radical inguinal orchiectomy. The session reinforced that suspected testicular cancer should not be delayed, particularly because some germ cell tumours can progress rapidly.
Staging was presented as a practical foundation for management. Tumour markers such as AFP, beta-HCG and LDH, together with nodal imaging and histology, help distinguish seminomatous from non-seminomatous disease and guide decisions on surveillance, chemotherapy, radiotherapy and retroperitoneal lymph node dissection. The discussion also highlighted the technical and fertility-related implications of retroperitoneal surgery in young men.
Dr. Joseph Abuodha reviewed advanced and relapsed disease, emphasising that treatment remains strongly anchored in surgery, cisplatin-based chemotherapy, radiotherapy and surveillance rather than newer targeted or immunotherapy approaches. Across stages, the emphasis was on matching intensity to risk—avoiding both overtreatment and undertreatment—while recognising that even metastatic disease can remain curable with the right treatment strategy.
Dr. George Ogweno brought fertility preservation into the core of cancer care. He underscored the need for early oncofertility counselling, sperm banking where possible before treatment, and stronger collaboration between oncology, urology, fertility specialists, laboratories and counsellors. The discussion also reflected Kenya’s service realities, including limited fertility centres and the need for clearer pathways, consent and long-term storage planning.
Across the session, a consistent message emerged: testicular cancer care must protect both survival and survivorship.
Key Takeaways

Early recognition, tumour markers, imaging and radical inguinal orchiectomy are central to initial management.
Risk stratification using histology, TNM stage and post-operative markers guides treatment intensity.
Seminoma and non-seminoma pathways differ and should not be managed interchangeably.
Cisplatin-based chemotherapy remains central in advanced and relapsed disease.
Surveillance is appropriate only when reliable follow-up is possible.
Fertility counselling and sperm preservation should be discussed as early as possible.

Bridging Surgery and Oncology in Head & Neck Cancer
2026-04-16 19:00 - 20:30
Moderator: Dr. Ahmed Komen
Speakers: Dr. Anthony Kenyanya, Dr. Anthony Ndiritu
Date: 16 April 2026

This session explored the management of head and neck cancer with particular attention to how surgical decisions and oncology pathways must align from the outset. Through oral cavity cancer as a key focus, the session examined resectability, margins, nodal management, reconstruction, adjuvant therapy and functional outcomes.
A central theme was that treatment planning must go beyond tumour removal. Dr. Anthony Kenyanya highlighted the importance of staging, imaging, pathology, dental and nutritional assessment, surgical access, margin planning and neck node evaluation. In oral cavity cancers, surgical success depends not only on clear oncologic resection, but also on the ability to reconstruct defects and preserve speech, swallowing, appearance and quality of life.
The discussion also emphasised the challenge of late presentation and complex anatomy. Selective neck dissection, sentinel node considerations, access procedures such as mandibulotomy, and the reconstructive ladder were framed as tools for balancing disease control with morbidity. The role of the pathologist and margin assessment was highlighted as central to determining risk and guiding further treatment.
Dr. Anthony Ndiritu built on this by outlining how radiotherapy and chemoradiation fit into early, locally advanced, post-operative, recurrent and metastatic diseases. Early-stage disease may often be treated with a single modality, while locally advanced disease requires careful integration of surgery, radiotherapy and chemotherapy.
Positive margins and extranodal extension were discussed as major indications for post-operative chemoradiation, with timely initiation of treatment after surgery being important. The session also addressed treatment technique, patient fitness, nutrition, supportive care and the need to tailor recommendations to the services and expertise available.
Across the session, a consistent message emerged: head and neck cancer care is as much about function, coordination and follow-through as it is about disease control.
Key Takeaways

Head and neck cancer decisions must integrate tumour stage, resectability, patient fitness and functional outcomes.
Margin planning, pathology reporting and neck node assessment directly shape adjuvant treatment decisions.
Surgery requires strong reconstruction and rehabilitation planning to preserve speech, swallowing and appearance.
Locally advanced disease often needs combined-modality treatment through an MDT approach.
Positive margins and extranodal extension are key triggers for post-operative chemoradiation.
Supportive care, nutrition and patient navigation are essential to treatment completion.

Treatment in Esophageal Cancer
2026-04-09 19:00 - 20:30
THE ROLE OF MULTIMODAL Treatment in Esophageal Cancer
Date: 9th April 2026 Time: 7 PM – 8:30 PM EAT
MODERATOR
Dr. Omar Abdihamid Clinical Oncologist, Garissa Regional Cancer Center | Vice President (EA), African Organisation for Research and Training in Cancer
SPEAKERS
Dr. Juma Odoro Cardiothoracic and vascular surgeon, JOOTRH Kisumu and Head of Unit Surgical Management of Esophageal Cancer
Dr. Rogers Mongare Consultant Clinical and Radiation Oncologist at Kenyatta National Hospital (KNH) The Role of Radiotherapy in the Management of Esophageal Cancer
Dr. Kevin Makori Consultant Clinical & Radiation Oncologist, Homa Bay County Teaching and Referral Hospital | Clinical Trials Investigator, Victoria Cancer Care & Research Center, Nyamira Management of Metastatic Esophageal Cancer: Advances in Targeted and Combination Therapies

CLICK TO REGISTER

Optimizing Care in Colorectal Cancer
2026-03-26 19:00 - 20:30
Date: 26th March 2026
Time: 7 PM – 8:30 PM EAT
Moderator

Dr. Andrew Odhiambo Medical Oncologist, The Nairobi Hospital; Thematic Head & Program Director, Medical Oncology, UON

Speakers
Dr. Alex Muturi Colorectal Surgeon & Surgical Gastroenterologist, Kenyatta University Teaching, Research and Referral Hospital Locally Advanced Colon Cancer: Timing of Surgery Relative to Systemic Treatment
Dr. Caroline Tonio Medical Oncologist, Clinical Research Fellow (Clinical Trials), The Christie NHS Foundation Trust, UK & KUTRRH, Kenya “Too Young for Colorectal Cancer?” Understanding the rise of EOCRC and its clinical impact.

CLICK TO REGISTER

Renal Cell Carcinoma: Evidence-Based Integration of Surgery and Systemic Therapy
2026-03-19 19:00 - 20:30
Evidence-Based Integration of Surgery and Systemic Therapy
Date: 19th March 2026Time: 7 PM – 8:30 PM EAT
MODERATORDr. Amina K. HabibMedical Oncologist, Aga Khan University Hospital, Nairobi
Dr. Carnjini YogeswaranConsultant Urological Surgeon | Kenyatta National HospitalTopic: Surgical Management of Locally Advanced and Oligometastatic Renal Cell Carcinoma
Dr. Douglas NyandikaPhysician and Medical Oncologist | The Nairobi HospitalTopic: Adjuvant and Metastatic Systemic Therapy in Renal Cell Carcinoma
Highlights
This session examined the evolving management of renal cell carcinoma (RCC), focusing on how surgical and systemic approaches are increasingly integrated across the disease continuum.
A central theme was the importance of risk-adapted, multidisciplinary care, particularly in settings where many patients are still present with advanced diseases. While improved imaging has increased incidental detection globally, late-stage presentation remains common in Kenya, shaping both prognosis and treatment strategy.
From a surgical perspective, nephron-sparing surgery remains standard for localized diseases, while radical nephrectomy and complex resections play a critical role in locally advanced cases. In oligometastatic disease, cytoreductive nephrectomy and metastasis-directed therapy may offer benefit in carefully selected patients, particularly when integrated with systemic treatment strategies.
Systemic therapy has expanded significantly, with immune checkpoint inhibitors and targeted therapies now forming the backbone of treatment in advanced disease. Evidence from key trials demonstrates improved survival outcomes with combination regimens, reinforcing a shift towards early and strategic use of systemic therapy, particularly in metastatic and high-risk settings.
In the adjuvant setting, therapies such as pembrolizumab have shown disease-free and overall survival benefit in selected high-risk patients, highlighting the importance of post-surgical risk stratification and follow-up.
However, translating these advances into routine practice remains constrained by access, cost and infrastructure. The discussion underscored the need for context-specific treatment pathways, supported by multidisciplinary decision-making and strengthened health systems.
Across the session, a consistent message emerged: optimal RCC outcomes depend on deliberate integration—of surgery, systemic therapy and patient-centered decision-making.
Key Takeaways

RCC management requires integration of surgical and systemic therapies.
Late-stage presentation remains a key challenge in many settings.
Nephron-sparing and radical surgery remain central to localized and advanced disease.
Immunotherapy and targeted agents are transforming metastatic RCC outcomes.
Adjuvant therapy is increasingly relevant in high-risk post-surgical patients.
Access, cost and infrastructure continue to shape real-world implementation.

Multiple Myeloma Care in Western Kenya
2026-03-12 19:00 - 20:30
Event Title: The Journey of Multiple Myeloma Care in Western Kenya
Accreditation: CPD Accredited

Date: 12th March 2026
Time: 7 PM – 8:30 PM EAT
Organization: KESHO (Kenya Society of Haematology & Oncology)

Moderator:

Dr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist, Kenyatta National Hospital.

Speakers

Dr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification
Dr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing, Cellular Therapies and Risk-Adapted Strategies
Dr. Beatrice Melly: Clinical Haematologist, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access, Infrastructure and Multidisciplinary Integration
Hightlights

This session examined how multiple myeloma care is evolving within the Kenyan context, bringing together perspectives on diagnostics, treatment advances and system-level delivery.
A central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors, immunomodulatory agents and anti-CD38 therapies, translating these gains into routine practice remains uneven.
The discussion highlighted the importance of accurate and timely diagnosis, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions.
From a clinical perspective, modern management is increasingly risk-adapted, incorporating quadruplet induction regimens, autologous stem cell transplantation and maintenance strategies. Emerging therapies, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease, though access remains limited in many settings.
At a systems level, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships, integrating clinical care, training and research within a learning health system. The approach emphasizes improving access, strengthening diagnostic and treatment infrastructure, and embedding multidisciplinary care pathways to support patients across the disease course.
Across the session, a consistent message emerged: advancing myeloma care requires not only better therapies, but systems capable of delivering them.
Key Takeaways

Myeloma outcomes are improving with novel and combination therapies.
Accurate diagnosis and risk stratification are central to management.
Standard care includes quadruplet induction, ASCT and maintenance therapy.
CAR-T and bispecific antibodies are reshaping relapsed disease care.
Sustainable progress depends on access, infrastructure and integrated care models.

Women in Oncology
2026-03-05 19:00 - 20:30
Women in Oncology this International Women’s Day!
Join us for a powerful CPD Accredited webinar hosted by KESHO — Kenya Society of Haematology & Oncology
Date: 5th March 2026
Time: 7:00 PM – 8:30 PM EAT
Moderator:

Dr. Gladwell Kiarie — Medical Oncologist, The Nairobi Hospital

Speakers:

Prof. Verna Vanderpuye

Senior Consultant Clinical Oncologist & Deputy Director, National Centre of Radiotherapy, Oncology and Nuclear Medicine, Korle-bu Teaching Hospital, Accra, Ghana Topic: Legacy and Leadership: Mentorship from Women Advancing Oncology in Africa

Dr. Chemtai Mungo

Assistant Professor of Obstetrics and Gynaecology & Physician-Scientist, University of North Carolina at Chapel Hill Topic: Purpose-Driven Careers: Global Health, Research and Women’s Impact in Oncology

Dr. Anne Mwirigi

Consultant Haematologist and Assistant Professor, Aga Khan University Hospital Topic: Growing in Specialised Oncology: Lessons in Haematology

Prof. Nazik Hammad

Professor of Medical Oncology, Saint Michael’s Hospital and University of Toronto Topic: Building Impactful Careers in Global Oncology: Mentorship, Leadership and Equity in Cancer Care

Precision Pathways in Lymphoma
2026-02-26 19:00 - 20:30
Date: 26th February 2026Time: 7:00 PM – 8:30 PM (EAT)

Speakers
ModeratorDr Anne MwirigiConsultant Haematologist & Assistant Professor, AKUH
Dr Rohini RadiaConsultant in BMT and Haematology, Nairobi West HospitalStrategic Alignment in Lymphoma: From Precise Diagnosis to Clinical Excellence
Dr Jonathan WawireConsultant Anatomic Pathologist & Assistant Professor, AKUHLymphoma Diagnostic Algorithm in Routine Practice
Highlights
This session explored how lymphoma care is increasingly shaped by the alignment between diagnostic precision and therapeutic decision-making, particularly in settings where access to advanced diagnostics remains variable.
A central theme was the shift from morphology-led classification alone to a multi-parameter diagnostic approach, integrating clinical context, histopathology, immunophenotyping and where available, molecular profiling. As emphasized during the discussion, classification is no longer purely descriptive: it directly determines treatment pathways, prognosis and eligibility for emerging therapies.
Dr. Wawire outlined a structured diagnostic framework anchored on architecture, cytology and clonality, with morphology guiding the initial pathway and targeted immunohistochemistry refining classification. In routine practice, a focused IHC panel (CD20, CD3, CD5, CD10, Cyclin D1) remains sufficient to classify most lymphomas and support timely clinical decisions.
Importantly, the session addressed the practical realities of diagnostic limitations. The distinction between “Not Otherwise Specified (NOS)” and “Not Further Classified (NFC)” was highlighted as a clinically responsible approach where molecular testing is unavailable maintaining transparency while ensuring patients are still appropriately managed.
Building on this, Dr. Radia emphasized that improved outcomes depend on early alignment between diagnostics, treatment selection and delivery systems. In practice, delays in diagnostic workflows or limited access to molecular testing can directly influence treatment choices and patient outcomes making coordination across pathology, oncology and imaging essential.
As treatment options expand, from immunochemotherapy to targeted agents, CAR-T therapies and bispecific antibodies, the need for early risk stratification and timely decision-making becomes even more critical, particularly in balancing efficacy, cost and access within real-world settings.
Across the case discussions, a consistent message emerged: the quality and timeliness of diagnosis remain central to achieving better outcomes in lymphoma care.
Key takeaways:

Lymphoma classification now relies on integrated clinical, morphological and molecular assessment.
Focused IHC panels remain highly effective in routine and resource-limited settings.
“NFC” supports safe, transparent reporting when advanced testing is unavailable.
Diagnostic delays and access gaps can directly impact treatment decisions.
Early alignment across disciplines is essential to optimize outcomes.

Management of Biliary and Gall Bladder Tumours
2026-02-19 19:00 - 20:30
SUMMARY
Advances in the Multidisciplinary Management of Biliary and Gallbladder Tumours
Speakers: Prof. Elly Ogutu, Dr. Mohan Ramchandani, Dr. Kausik Bhattacharya, Dr. M. Vamshi Krishna
Date: 19 February 2026
This session examined the management of biliary and gallbladder tumours through a multidisciplinary lens, highlighting the importance of coordinated approaches across endoscopy, surgery and oncology in improving patient outcomes.
A central theme was the role of accurate and timely diagnosis, with particular emphasis on tissue acquisition and the contribution of advanced endoscopic techniques in guiding clinical decision-making. The discussion underscored how delays or limitations in diagnostic pathways can significantly influence treatment options and outcomes.
Through the KNH–UoN strategic training partnership and collaboration with the Asian Institute of Gastroenterology, the session reflected the value of regional expertise and diaspora engagement in strengthening clinical capacity and expanding access to specialised skills.
From a clinical perspective, evolving therapeutic strategies—including advances in surgical techniques and radiation oncology—were highlighted as critical components of care, particularly when integrated within a multidisciplinary framework that supports individualized treatment planning.
Across the session, a consistent message emerged: improving outcomes in biliary and gallbladder cancers will depend on strengthening diagnostic pathways and ensuring coordinated, multidisciplinary care across the patient journey.
Key Takeaways

Early and accurate diagnosis remains central to effective management.
Advanced endoscopic techniques play a key role in tissue sampling and staging.
Multidisciplinary coordination improves treatment planning and outcomes.
Regional and diaspora collaboration strengthens clinical capacity.
Integration of surgical, endoscopic and oncological care is essential.

Environmental Risks of Cancer
2026-02-12 08:00 - 17:00
Speakers: Dr. Mary Nyangasi, Dr. David Githanga, Dr. Carolina Espina
Date: 12 February 2026
Highlights
This session examined cancer risk through an environmental and public health lens, highlighting the extent to which cancer burden is shaped by modifiable exposures rather than biology alone. A central theme was the recognition that cancer is not only a clinical or genetic condition, but also a social and environmental disease, with a substantial proportion of cases linked to preventable risk factors. Global evidence suggests that up to 40% of cancers are attributable to modified exposures, including environmental and occupational risks. Dr. Githanga outlined the biological mechanisms through which environmental exposures drive carcinogenesis, including DNA damage, chronic inflammation, epigenetic dysregulation and impaired immune surveillance. These pathways act cumulatively over time, often with long latency periods between exposure and disease manifestation.
Real-world examples such as air pollution, aflatoxin exposure and oncogenic infections illustrate how environmental context directly shapes cancer patterns, particularly in low- and middle-income settings where exposure levels are higher and regulatory systems less robust. Building on this, Dr. Nyangasi emphasized that a significant proportion of cancer burden is preventable, with WHO frameworks highlighting the importance of population-level interventions targeting modifiable risk factors, including environmental regulation, vaccination and lifestyle-related risks.
Dr. Espina introduced the World Code Against Cancer framework, which translates complex scientific evidence into clear, actionable recommendations for individuals, health systems and policymakers. The framework underscores the importance of moving beyond individual behavior change towards coordinated, multi-sectoral prevention strategies. Across the session, a consistent message emerged: meaningful reductions in cancer burden will depend on shifting upstream towards prevention, regulation and system-level action
Key Takeaways

A substantial proportion of cancers are linked to modifiable environmental and behavioral exposures.
Environmental carcinogenesis occurs through multi-pathway biological mechanisms over time.
Exposure to risk is uneven and shaped by social and economic conditions.
Population-level interventions have greater impact than individual behavior change alone.
Effective cancer control requires alignment between clinical practice, public health and policy.

World Cancer Day
2026-02-05 19:00 - 20:30 | Virtual Event (Zoom), Kenya
World Cancer Day:
United by Unique – The Kenyan Perspective
Date: 5th February 2025Time: 7:00 PM – 8:30 PM (EAT)
Moderator
Dr. Gladwell KiarieMedical Oncologist, The Nairobi Hospital
Speakers
Hon. Dr. Ouma OlugaPrincipal Secretary for the State Department for Medical Services,Ministry of Health, Kenya
Hon. Dr. James NyikalChairperson of the National Assembly Departmental Committee on Health, Kenya
Dr. Mercy MwangangiChief Executive Officer, Social Health Authority
Dr. Elias MellyChief Executive Officer, National Cancer Institute, Kenya
Dr. Ahmed OgwellPublic Health Expert, CEO & President, VillageReach
Prisca GithukaVice-Chairperson & Advocacy Chair,Kenyan Network of Cancer Organizations (KENCO) and Chairlady,Cancer Survivors Association of Kenya
Highlights
This session brought together clinical, policy and advocacy voices to reflect on the current state of cancer care in Kenya, with a focus on how systems, leadership and lived experience intersect to shape outcomes.
A central theme was the need to move beyond fragmented approaches towards coordinated, patient-centered cancer control, grounded in national priorities and responsive to the realities of care delivery. The discussion highlighted that improving outcomes requires not only clinical excellence, but also alignment across policy, financing and implementation.
Speakers emphasized the importance of strengthening health systems to support prevention, early detection and access to treatment, while addressing structural barriers that continue to limit equitable care. The role of national institutions, policy frameworks and cross-sector collaboration emerged as critical in driving sustainable progress.
Patient voice and lived experience were also highlighted as essential to shaping responsive and inclusive cancer care strategies, ensuring that interventions reflect the needs and realities of those most affected.
Across the discussion, a consistent message emerged: meaningful progress in cancer control will depend on alignment between policy, practice and people.
Key Takeaways

Effective cancer control requires alignment across clinical care, policy and implementation.
Strengthening health systems is essential to improving access, equity and outcomes.
Prevention and early detection remain critical entry points for reducing burden.
Patient voice and lived experience are key to responsive, person-centered care.
Sustainable progress depends on multi-sector collaboration and leadership.

Watch the full session here:

Watch Video

HPV Vaccine Campaign/Outreach Screening
2026-01-31 08:00 - 17:00

Cervical Cancer Prevention and Control In Kenya
2026-01-22 19:00 - 20:30
(CPD Accredited)
Date & Time: 22nd January 2026 7 PM – 8:30 PM (EAT)

Moderator: Dr. Benjamin Elly Odongo
Obstetrician/Gynecologist & Gynaecologic Oncologist, Senior Lecturer & Chairman, Department of Obstetrics & Gynaecology, Kenyatta University School of Health Sciences

Speakers:
Prof. Lucy Muchiri
Associate Professor in the Department of Human Pathology, University of Nairobi’s School of Medicine
Topic: Overview of the WHO 90-70-90 cervical cancer elimination strategy and implications for pathology services
Prof. Omu Anzala Professor of Virology and Immunology, Department of Medical Microbiology; Senior Research Scientist at KAVI – Institute of Clinical Research (KAVI – ICR), University of Nairobi, Kenya
Topic: HPV Vaccination in Kenya: Scientific Evidence, Immunological Perspectives, and Public Controversies
Dr. Richa Bansal Gynecological Oncologist and Robotic Surgeon, Apollo Hospitals, Navi Mumbai, India
Topic: Cervical Cancer Prevention and Advanced Treatment
Highlights
This session examined cervical cancer through the lens of prevention, highlighting it as one of the few cancers where elimination is both feasible and within reach.
A central theme was the WHO 90-70-90 strategy, which outlines a clear pathway to elimination through HPV vaccination, screening and timely treatment. Achieving these targets could reduce cervical cancer incidence to below 4 cases per 100,000 women, effectively transforming it into a rare disease.
The discussion emphasized that cervical cancer is almost entirely driven by persistent HPV infection, making it uniquely preventable through vaccination and early detection. Evidence shows that HPV vaccines are highly effective, with strong and sustained protection against high-risk HPV types responsible for most cases.
Despite this, the burden remains disproportionately high in low- and middle-income settings, including Kenya, where gaps in screening coverage, diagnostic capacity and referral pathways continue to limit early detection and timely treatment.
The role of pathology services emerged as critical, forming the diagnostic backbone for screening programs and treatment decisions. Expanding HPV DNA testing, strengthening laboratory systems and investing in workforce development were identified as key priorities for achieving national targets.
Across the session, a consistent message emerged: cervical cancer is preventable and eliminating it will depend on scaling what already works.
Key Takeaways

Cervical cancer is one of the few cancers where elimination is achievable.
The WHO 90-70-90 targets provide a clear, evidence-based roadmap.
HPV vaccination and screening are high-impact prevention strategies.
Strengthening pathology and diagnostic capacity is essential to progress.
Closing gaps in access and coverage is critical to achieving equitable outcomes.

Multiple Myeloma
2025-12-22 08:00 - 17:00

Bladder and Urothelial Cancer Treatment
2025-12-11 19:00 - 20:30
Moderator:
Dr. Thomas OdenyMedical Oncologist, Assistant Professor of Medicine,Washington University in St. Louis
Speakers:
Dr. Primus OchiengLecturer, Programme Director – MMed Radiation Oncology& Founder, UNITED Oncology Clinical Trial Centre, UoNRadiotherapy in Bladder Cancer: Current Evidence and Clinical Applications
Dr. DK KimaniConsultant Surgeon & Urologist, Kenyatta National Hospital, NairobiBladder & Urothelial Cancer in Kenya: Bridging Treatment Innovations and Local Realities
Dr. Andrea ApolloSenior Investigator, Genitourinary Malignancies Branch, NCI, USAManagement of bladder cancer: Clinical trials and research updates

Cancer-Related Thrombosis
2025-12-04 19:00 - 20:30
Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis
Presentation by Dr Laura Kirui
Dr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT), addressing its epidemiology, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum.
The presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation, dysregulated fibrinolysis, and tumor host cellular interactions were reviewed to contextualize clinical risk.
Emphasis was placed on risk stratification, particularly the use of validated tools such as the Khorana score, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed, alongside bleeding considerations. The session also addressed therapeutic anticoagulation, duration of treatment, secondary prophylaxis and management in special scenarios including thrombocytopenia, catheter-related thrombosis and incidental VTE.
Key takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.

Management of Pancreatic Cancer
2025-11-27 19:00 - 20:30
CPD ACCREDITED
Management of Pancreatic Cancer
Date:27th November 2025
Time:7 PM – 8:30 PM EAT

Moderator
Dr. Karan GandhiConsultant Hepatobiliary, General and Laparoscopic Surgeon at 3rd Park Hospital, Nairobi

SPEAKER
Dr. Sakulen A HarguraConsultant Hepatobiliary, General & Laparoscopic Surgeon, Kenyatta University Teaching, Research and Referral Hospital, NairobiTopic: Surgical Dilemmas in Pancreatic Cancer, “Who, When & How”

SPEAKER
Dr. Andrew OdhiamboMedical Oncologist – The Nairobi HospitalThematic Head & Program Director – Medical Oncology, UONTopic: Balancing Quality Vs Quantity of Life – Oncologist Role in Stage 4 Pancreatic Cancer
SPEAKER
Joyce AwuorConsultant Dietitian Nutritionist, Founder and CEO of DietSelect254Topic: The Ideal Diet for A Failing Pancreas
KESHOKenya Society of Haematology & Oncology

Management of Non-Small Cell Lung Cancer
2025-11-20 19:00 - 2025-11-22 20:30
BRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer
Date: 20th November 2025Time: 7 PM – 8:30 PM EAT
(CPD ACCREDITED)

Moderator
Dr. Muhindi WanjuguPhysician and Chest Specialist, The Nairobi Hospital, Doctors Plaza, Nairobi

Speakers
Dr. Nuruddin JoomaHaemato-Oncologist, Florida Cancer Specialists & Research Institute, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer
Dr. Morris MuhingaConsultant Cardiothoracic Surgeon, The Nairobi HospitalShift in Surgical Paradigm
Summary:
Lung Cancer: Contemporary Clinical Management and Emerging Evidence
Presentations by Dr Nuruddin Jooma and Dr Morris Muhinga
The sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing.
Key clinical principles discussed included optimal diagnostic pathways incorporating imaging, histopathology and immunohistochemistry, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection, avoid inappropriate use of immunotherapy and improve survival outcomes.
Current standards of care were reviewed across disease stages, including surgical management in early-stage disease, the expanding role of neoadjuvant and adjuvant systemic therapies, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms.
Both presentations reinforced the need for timely diagnosis, biomarker-driven treatment decisions and coordinated multidisciplinary care, while acknowledging ongoing challenges related to access, treatment sequencing and long-term disease control.
Key takeaway: Optimal lung cancer outcomes depend on precise staging, comprehensive molecular testing and evidence-based, multidisciplinary treatment across the disease continuum.

Advances in Small-Cell Lung Cancer Treatment
2025-11-13 19:00 - 20:30
Date: 13th November 2025Time: 7 PM – 8:30 PM EAT

SpeakerDr. Riaz KasmaniMedical Oncologist, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances, Evidence and Clinical Challenges

ModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head, Pulmonology, Aga Khan Hospital

Organized by:KESHOKenya Society of Haematology & Oncology
Supported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited)
Summary:
Dr Kasmani presented an overview of Small Cell Lung Cancer (SCLC), focusing on disease biology, treatment response, relapse patterns and emerging research directions.
SCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive, with high response rates to first-line therapy, relapse is common and subsequent responses are often short-lived.
The presentation highlighted current staging approaches, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment, patterns of relapse and the clinical distinction between sensitive and refractory disease, which continues to guide second-line treatment decisions.
Key takeaway: Despite high initial response rates, SCLC remains a challenging disease with frequent relapses, underscoring the need for timely diagnosis, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.
